Cytosorbents Corporation
CTSO
$0.59
$0.000.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.12% | 23.89% | 20.18% | 15.37% | 14.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.12% | 23.89% | 20.18% | 15.37% | 14.51% |
| Cost of Revenue | -1.27% | 74.01% | 87.00% | 53.19% | 17.26% |
| Gross Profit | 6.44% | 10.37% | 2.84% | 3.64% | 13.37% |
| SG&A Expenses | 4.94% | -9.36% | -12.06% | -14.40% | -11.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.88% | -4.70% | -7.05% | -13.96% | -17.36% |
| Operating Income | 14.70% | 41.00% | 38.57% | 45.03% | 48.17% |
| Income Before Tax | 61.62% | 39.82% | 57.14% | 38.25% | 25.45% |
| Income Tax Expenses | 76.29% | -157.10% | -107.82% | -107.82% | -107.82% |
| Earnings from Continuing Operations | 60.43% | 47.94% | 62.27% | 42.49% | 29.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.43% | 47.94% | 62.27% | 42.49% | 29.16% |
| EBIT | 14.70% | 41.00% | 38.57% | 45.03% | 48.17% |
| EBITDA | 15.74% | 43.73% | 40.89% | 47.46% | 50.82% |
| EPS Basic | 65.48% | 52.48% | 66.20% | 51.26% | 42.05% |
| Normalized Basic EPS | 70.56% | 47.20% | 62.51% | 48.47% | 39.82% |
| EPS Diluted | 65.28% | 52.31% | 66.06% | 51.11% | 41.91% |
| Normalized Diluted EPS | 70.05% | 46.69% | 62.14% | 48.47% | 39.82% |
| Average Basic Shares Outstanding | 14.22% | 14.81% | 16.45% | 18.39% | 22.00% |
| Average Diluted Shares Outstanding | 16.31% | 16.98% | 18.73% | 18.39% | 22.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |